Coherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million
Coherus Oncology Inc. reported third quarter 2025 net revenue from continuing operations of $11.6 million, up from $6.1 million in the same period in 2024. Net revenue for the nine months ended September 30, 2025 was $29.4 million, compared to $18.7 million for the same period in 2024. LOQTORZI net product revenue increased by $5.3 million year-over-year for the quarter, primarily due to volume growth following its launch in December 2023. Non-GAAP net loss from continuing operations for the third quarter was $38.9 million, or $(0.33) per diluted share, compared to $40.0 million, or $(0.35) per diluted share in the prior year period. Cash, cash equivalents, and marketable securities totaled $191.7 million at the end of the quarter. Selling, general and administrative expenses for the quarter were $24.9 million, down from $28.1 million in the same quarter of 2024, reflecting lower headcount and decreased operating costs following recent divestitures. The CHS-114 clinical program was expanded to include colorectal cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570915-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.